Definium Therapeutics
Definium Therapeutics Inc is an American clinical-stage biopharmaceutical company developing targeted small molecule therapeutics for oncology and rare diseases. The company discovers and advances precision drug candidates designed to inhibit key disease-driving kinase pathways in solid tumors and hematological malignancies. Main revenue drivers currently consist of investment capital financing, research partnership grants, and potential milestone licensing fees as clinical trials progress. Definium Therapeutics targets medical oncologists, hematology specialists, clinical trial centers, and oncology patients across North America. The company holds an innovative position in precision kinase targeting and oncology biopharmaceutical pipeline development. Headquartered in the United States, Definium Therapeutics Inc operates as a private biopharmaceutical enterprise.
3 of the funds FundTelligence covers report a position in Definium Therapeutics.
- Legal name
- Definium Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Definium Therapeutics
- SEB Läkemedelsfond — SEB · 0.54 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.29 % (full portfolio disclosed, October 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.27 % (full portfolio disclosed, September 2026)